cagrisema vs retatrutide CagriSema: The Battle Nobody's Covering ADA: Novo CSO says 'jury

According to the ICER, Wegovy should be priced at $7,500$9,800 per year to fall into the cost-effective threshold

This evidence-based approach aims to optimize patient outcomes and support sustained weight management

But we need to unpack what weight loss actually means, because theyre conflating several distinct phenomena: First, you dont need to be overweight to benefit from fat loss

Lilly's recently released research data indicates that all doses of Retatrutide significantly reduced liver fat content at week 48 compared to the placebo group

Shares of Novo Nordisk were down 2.7% Thursday afternoon, while those of Eli Lilly were up about 1%.